TCGA-O2-A52W-01A-11R-A26W-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.360
- KRAS_SIGNALING_DN+0.330
- SPERMATOGENESIS+0.290
- G2M_CHECKPOINT+0.270
- WNT_BETA_CATENIN_SIGNALING+0.200
- ESTROGEN_RESPONSE_LATE+0.140
- MYC_TARGETS_V2+0.120
- PANCREAS_BETA_CELLS+0.110
- TNFA_SIGNALING_VIA_NFKB+0.100
- APICAL_SURFACE+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- PROTEIN_SECRETION-0.510
- OXIDATIVE_PHOSPHORYLATION-0.440
- TGF_BETA_SIGNALING-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- DNA_REPAIR-0.390
- PI3K_AKT_MTOR_SIGNALING-0.380
- ADIPOGENESIS-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- HEME_METABOLISM-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303774 | — | — | 0.868 |
| 2 | SRR6013541 | — | cohortSQ1 | 0.859 |
| 3 | SRR6013518 | — | cohortSQ1 | 0.833 |
| 4 | SRR650159 | — | — | 0.821 |
| 5 | SRR1797259 | — | cohortSC | 0.819 |
| 6 | SRR8943030 | — | — | 0.819 |
| 7 | SRR22247242 | — | cohortSC | 0.814 |
| 8 | BS_JVW2JJ39 | high-grade glioma | — | 0.811 |
| 9 | MNG459 | — | — | 0.810 |
| 10 | MNG370 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |